Po-Yu Chen

Po-Yu Chen

Auto-generated profile, based on publicly available information

Po-Yu Chen

Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Psychiatric Research Center, Wang Fang Hospital, Taipei Medical University, Taipei, Taiwan; Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan; Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2009 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
PCPo‐Yu Chen
Po‐Yu Chen
SWSheng‐Chang Wang
Sheng‐Chang Wang
RPRussell E. Poland
Russell E. Poland
KLKeh‐Ming Lin
Keh‐Ming Lin
Ethnicity and culture represent important factors in shaping psychopathology as well as pharmacotherapeutic responses in psychiatric patients. A large body of literature, accumulated over the past several decades, demonstrates that these factors not only determine the metabolism and disposition of medications (pharmacokinetics), but also their interactions with therapeutic targets (pharmacodynamics). This article focuses on the impact of such variations on the diagnosis and treatment of depression and anxiety disorders between East and West. Genes controlling the expression of drug metabolizing enzymes as well as the function of the brain are highly polymorphic, and the patterns and distribution of these polymorphisms are typically divergent across ethnic groups. To the extent that these genetic patterns determine drug response, ethnic variations in these genetic dispositions will lead to differential responses in clinical settings. In addition, the expression of these genes is significantly influenced by environmental factors including diet as well as exposure to other natural products. Superimposed on these biological influences, culturally determined beliefs and behavioral patterns also profoundly influence patients’ expectations of treatment response, adherence, and interactions with clinicians. In addition to pharmacotherapeutic responses, emerging data also indicate that significant ethnic variations exist in genetic polymorphisms and neurobiologic correlates (biomarkers) that may be associated with the vulnerability to psychiatric disorders. These considerations argue for the importance of examining biological variations across ethnic groups, especially in the clinical context, in terms of the assessment and treatment of psychiatric patients, and in our understanding of psychiatric phenomenology and nosology.

1 June 2019 in Psychiatry Research
Verified
Journal Article
Closed access
TWTzu-Hua Wu
Tzu-Hua Wu
CCChih-Chiang Chiu
Chih-Chiang Chiu
PCPo-Yu Chen
Po-Yu Chen
MHMing-Chyi Huang
Ming-Chyi Huang
CCChun-Hsin Chen
Chun-Hsin Chen
MLMong-Liang Lu
Mong-Liang Lu

9 October 2021 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
YLYen-Feng Lin
Yen-Feng Lin
PCPo-Yu Chen
Po-Yu Chen
HLHsing-Cheng Liu
Hsing-Cheng Liu
YCYi-Lung Chen
Yi-Lung Chen
WCWei-Hern Chou
Wei-Hern Chou
MHMing-Chyi Huang
Ming-Chyi Huang
Methamphetamine (METH) use, most prevalent in young adults, has been associated with high rates of morbidity and mortality. The relationship between METH use and accelerated biological aging, which can be measured using leukocyte telomere length (LTL), remains unclear. We examined whether young adult METH users have shorter LTL and explored the relationship between characteristics of METH use and LTL by using Mendelian randomization (MR) analysis. We compared the LTL for 187 METH users and 159 healthy individuals aged between 25 and 34 years and examined the relationship of LTL with METH use variables (onset age, duration, and maximum frequency of METH use) by using regression analyses. In addition, 2-stage-least-squares (2SLS) MR was also performed to possibly avoid uncontrolled confounding between characteristics of METH use and LTL. We found METH users had significantly shorter LTL compared to controls. Multivariate regression analysis showed METH use was negatively associated with LTL (β = −0.36, P < .001). Among METH users, duration of METH use was negatively associated with LTL after adjustment (β = −0.002, P = .01). We identified a single nucleotide polymorphism (SNP) rs6585206 genome-wide associated with duration of METH use. This SNP was used as an instrumental variable to avoid uncontrolled confounding for the relationship between the use duration and LTL shortening. In conclusion, we show that young adult METH users may have shorter LTL compared with controls and longer duration of METH use was significantly associated with telomere shortening. These observations suggest that METH use may accelerate biological senescence.

27 July 2024 in Asian Journal of Psychiatry
Verified
Journal Article
Closed access
ACAn-Nie Chung
An-Nie Chung
MHMing-Chyi Huang
Ming-Chyi Huang
TLTung-Hsia Liu
Tung-Hsia Liu
HCHu-Ming Chang
Hu-Ming Chang
PCPo-Yu Chen
Po-Yu Chen
FBFrancesco Bavato
Francesco Bavato

1 October 2021 in Environmental Toxicology and Pharmacology
Verified
Journal Article
Closed access
HCHu-Ming Chang
Hu-Ming Chang
PCPo-Yu Chen
Po-Yu Chen
CFChiu-Ping Fang
Chiu-Ping Fang
TLTung-Hsia Liu
Tung-Hsia Liu
CWChun-Te Wu
Chun-Te Wu
MHMing-Chyi Huang
Ming-Chyi Huang

6 December 2024 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
CCChun-Hsin Chen
Chun-Hsin Chen
CCChih-Chiang Chiu
Chih-Chiang Chiu
YCYi-Hang Chiu
Yi-Hang Chiu
CCChin-Hao Chang
Chin-Hao Chang
YCYu-Han Chang
Yu-Han Chang
PCPo-Yu Chen
Po-Yu Chen
We aimed to evaluate the effects of folate and vitamin B12 on psychopathology in patients with schizophrenia and low serum folate levels. Fifty-five schizophrenia patients with serum folate levels lower than 6 mg/L were randomized in a 2:1 ratio to supplementation with 5 mg of folate and 500 μg of vitamin B12 per day (the folate group, n = 36) or placebo (the placebo group, n = 19) for 24 weeks. We evaluated patients' symptomatology with the Positive and Negative Symptom Scale (PANSS) and cognitive functions with Cogstate. During the 24-week intervention, serum folate and vitamin B12 levels significantly increased, and homocysteine level significantly decreased in the folate group, but these markers did not significantly change in the placebo group. There were no significant changes in scores of total and each subscale of PANSS, and Cogstate between the folate and placebo groups. A subgroup analysis within the folate groups revealed no significant differences in the changes of psychotic symptoms severity or cognitive functions among patients with different degrees of folate level increments. Our finding suggested that the extent of increased folate levels did not exert a notable impact on the changes of psychotic symptoms severity or cognitive function in our patients. It may also due to the relatively stable condition in our recruited patients, so supplementation of folate cannot show its effectiveness. Whether folate can improve psychopathology in moderate to severe patients with schizophrenia should be evaluated with a larger sample size in the future.